As various trends in the life sciences industry come and go, the growth of Real-World Evidence (RWE) is here to stay. We find ourselves at a turning point as the range of RWE-driven applications has drastically increased from demonstrating a product's efficacy to leveraging phenotypic data to power target identification to expanding market access. Additionally, the increasing acceptance and direction provided by regulatory agencies points towards growing adoption in the industry. With this momentum, biopharmaceutical manufacturers are increasingly looking for ways to turn the massive amounts of Real-World Data (RWD) into actionable, value-driving evidence.

This webinar will address challenges encountered when leveraging RWE such as finding the “right” data set, identifying high priority use cases to show quick wins, and creating integrated evidence plans across a product’s lifecycle. Examples of how RWE has generated value for different organizations and an actionable playbook for turning RWD into "insight-ready" data will be shared.

Featured Speakers

Arnaub Chatterjee

SVP, Product and Ecosystem
Acorn AI, a Medidata Company

Arnaub is driving efforts around the development, go-to-market and delivery of capabilities that help life science clients accelerate their innovation. Arnaub serves as a Teaching Associate in the Department of Health Care Policy at Harvard Medical School and is a Lecturer in the Department of Policy Analysis and Management at Cornell University.

Bruno Lempernesse

VP & General Manager, Real World Evidence
SHYFT, a Medidata Company

Bruno leads SHYFT's evidence strategy along with a comprehensive team of experts in RWD, RWE, and data science. He focuses on executing and accelerating the evidence generation strategies of SHYFT's biopharma and CRO partners. Prior to joining SHYFT, Bruno has held several leadership roles in healthcare technology solutions, RWE, and data science/analytics at global levels.  

NOW AVAILABLE ON-DEMAND

Register now for this webinar